Skip to main content

Table 4 ACQ, FEV1 and OCS at baseline vs 16 weeks

From: 4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

 

Baseline

16 weeks

ACQ

 n

334

307

 Mean (SD)

2.96 (1.12)

1.83 (1.12)

  

p < 0.001

FEV1

 n

338

287

 Mean (SD)

71.58 (19.6)

79.06 (20.06)

  

p < 0.001

OCS

 n

364

334

 None (%)

242 (66.5)

241 (72.2)

 1–5 mg (%)

45 (12.4)

46 (13.8)

 6–9 mg (%)

15 (4.1)

12 (3.6)

 >10 mg (%)

61 (16.8)

35 (10.5)

  

p < 0.001